{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:52:24Z","timestamp":1792011144397,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1997,12,1]],"date-time":"1997-12-01T00:00:00Z","timestamp":880934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1997,12,1]],"date-time":"1997-12-01T00:00:00Z","timestamp":880934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1997,12]]},"DOI":"10.1023\/a:1005981317532","type":"journal-article","created":{"date-parts":[[2002,12,21]],"date-time":"2002-12-21T19:10:48Z","timestamp":1040497848000},"page":"331-341","source":"Crossref","is-referenced-by-count":62,"title":["A Phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors"],"prefix":"10.1007","volume":"15","author":[{"given":"Randall","family":"Brand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Capadano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Tempero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"153526_CR1","first-page":"4417","volume":"40","author":"LW Hertel","year":"1990","unstructured":"Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Rindey GB: Evaluation of the antitumor activity of gemcitabine (2\u2032,2\u2032-Difluoro-2\u2032-deoxycytidine). Cancer Res 40:4417\u20134422, 1990","journal-title":"Cancer Res"},{"key":"153526_CR2","first-page":"163","volume":"2","author":"GB Grindey","year":"1990","unstructured":"Grindey GB: Current status of cancer drug development: Failure or limited success? Cancer Cells 2:163\u2013171, 1990","journal-title":"Cancer Cells"},{"key":"153526_CR3","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/JCO.1994.12.9.1821","volume":"12","author":"H Anderson","year":"1994","unstructured":"Anderson H, Lund B, Back F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821\u20131826, 1994","journal-title":"J Clin Oncol"},{"key":"153526_CR4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1200\/JCO.1994.12.8.1535","volume":"12","author":"RP Abratt","year":"1994","unstructured":"Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg T: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1535\u20131540, 1994","journal-title":"J Clin Oncol"},{"key":"153526_CR5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00873232","volume":"12","author":"ES Casper","year":"1994","unstructured":"Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gemcitabine (2,2\u2032-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29\u201334, 1994","journal-title":"Invest New Drugs"},{"key":"153526_CR6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/oxfordjournals.annonc.a058775","volume":"5","author":"CF Pollera","year":"1994","unstructured":"Pollera CF, Ceribelli A, Crecco M, Calabreso F: Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182\u2013184, 1994","journal-title":"Ann Oncol"},{"key":"153526_CR7","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","volume":"86","author":"B Lund","year":"1994","unstructured":"Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP: Phase II study of gemcitabine (2\u2032,2\u2032-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Nat Cancer Inst 86:1530\u20131533, 1994","journal-title":"J Nat Cancer Inst"},{"key":"153526_CR8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a058910","volume":"5","author":"G Catimel","year":"1994","unstructured":"Catimel G, Vermorken JB, Clavel M, Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J, Franklin H, Kaye SB: A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:543\u2013647, 1994","journal-title":"Ann Oncol"},{"key":"153526_CR9","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.1995.13.11.2731","volume":"13","author":"J Carmichael","year":"1995","unstructured":"Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731\u20132736, 1995","journal-title":"J Clin Oncol"},{"key":"153526_CR10","first-page":"3","volume":"22","author":"W Plunkett","year":"1995","unstructured":"Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V: Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3\u201310, 1995","journal-title":"Semin Oncol"},{"key":"153526_CR11","first-page":"6823","volume":"50","author":"R Grunewald","year":"1990","unstructured":"Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W: Pharmacologically directed design of the dose rate and schedule of 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823\u20136826, 1990","journal-title":"Cancer Res"},{"key":"153526_CR12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","volume":"9","author":"JL Abbruzzese","year":"1991","unstructured":"Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491\u2013498, 1991","journal-title":"J Clin Oncol"},{"key":"153526_CR13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.1992.10.3.406","volume":"10","author":"R Grunewald","year":"1992","unstructured":"Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W: Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406\u2013413, 1992","journal-title":"J Clin Oncol"},{"key":"153526_CR14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00874440","volume":"12","author":"CF Pollera","year":"1994","unstructured":"Pollera CF, Ceribelli A, Crecco M, Calabresi F: Weekly gemcitabine in advanced or metastatic solid tumors. Invest New Drugs 12:111\u2013119, 1994","journal-title":"Invest New Drugs"},{"key":"153526_CR15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0959-8049(94)90276-3","volume":"30A","author":"TJ O'Rourke","year":"1994","unstructured":"O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee WG, Tarassoff PG, VonHoff DD: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days [letter]. Eur J Cancer 30A:417\u2013418, 1994","journal-title":"Eur J Cancer"},{"key":"153526_CR16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00877241","volume":"10","author":"EAD Poplin","year":"1992","unstructured":"Poplin EAD, Corbett T, Flaherty L, Tarassoff P, Redman BG, Valdivieso M, Baker L: Difluorodeoxycytidine (dFdC, gemcitabine): A phase I study. Invest New Drugs 10:165\u2013170, 1992","journal-title":"Invest New Drugs"},{"key":"153526_CR17","first-page":"379","volume":"7","author":"M Clavel","year":"1989","unstructured":"Clavel M, Guastella J, Peters G: Phase I study of LY-188011, 2\u2032,2\u2032-difluorodeoxycytidine. Invest New Drugs 7:379, 1989","journal-title":"Invest New Drugs"},{"key":"153526_CR18","first-page":"371","volume":"14","author":"FV Fossella","year":"1995","unstructured":"Fossella FV, Lippman SM, Tarassoff P, Shin DM, Calayag M, Lee JS, Murphy WK, Perez-Soler R, Glisson BS, Hong WK: Phase I\/II study of gemcitabine: An active agent for non-small cell lung cancer (NSCLC). Proc ASCO 14:371, 1995 (abstr 1144)","journal-title":"Proc ASCO"},{"key":"153526_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00001813-199512006-00005","volume":"6","author":"M Tonato","year":"1995","unstructured":"Tonato M, Mosconi AM, Martin C: Safety profile of gemcitabine. Anti-Cancer Drugs 6:27\u201332, 1995","journal-title":"Anti-Cancer Drugs"},{"key":"153526_CR20","first-page":"199","volume":"14","author":"M Moore","year":"1995","unstructured":"Moore M, Andersen J, Burrls H, Tarassoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Nelson R, Storniolo A, VonHoff D: A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer. Proc ASCO 14:199, 1995 (abstr 473)","journal-title":"Proc ASCO"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005981317532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1005981317532\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005981317532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:50:28Z","timestamp":1753818628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1005981317532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,12]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,12]]}},"alternative-id":["153526"],"URL":"https:\/\/doi.org\/10.1023\/a:1005981317532","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,12]]}}}